HCG margin trails healthcare peers as expansion costs weigh
Management said volume growth led the quarter, but North Bangalore startup losses and an EPCG provision reduced reported EBITDA.
Filed 06 Aug 2026, 19:03 IST · after market close · Healthcare Global Enterprises Ltd (HCG)
Key takeaways
- HCG's consolidated operating margin of 17.59% was 4.46 percentage points below the median for 45 healthcare peers.
- Management said Q1FY27 revenue growth was led by 11% year-on-year volume growth, while ARPP increased 2%.
- Management said 121 operational beds were added, including 56 at North Bangalore, which generated Rs 67 million of Q1FY27 revenue.
Price around the results
Volume growth did not close the margin gap
HCG reported consolidated Q1FY27 results with revenue growth led by an 11% year-on-year increase in volumes, while ARPP rose 2%, management said. Its 17.59% operating margin was 4.46 percentage points below the 22.05% median among 45 healthcare peers that had reported the quarter. This places HCG 11th from the bottom of that peer set.
North Bangalore and case mix affected profitability
Management said North Bangalore's startup losses of Rs 70 million and an EPCG-related provision of Rs 46 million reduced reported EBITDA. It also said higher medical oncology volumes and a shift away from high-value, lower-margin therapies offset the benefit from payor mix. In the East region, ARPP declined 3% year on year because of case-mix changes and a higher contribution from state-government schemes.
Bed additions broaden the operating base
North Bangalore began operations in May 2026 with 56 operational beds and recorded more than 550 new patient registrations, over 300 admissions and Rs 67 million of revenue in Q1FY27, management said. The company told analysts that it plans to add 1,000 beds by FY30, with 60% of the expansion through brownfield projects. Management also said North Bangalore could expand beyond 120 beds and that its MR Linac, commissioned in July 2026, is expected to enhance clinical capability and drive patient volume.
Results were filed after market close
The consolidated results were filed after market close on 6 August 2026. The stock's post-results move is therefore not yet part of the reported market reaction.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹695 cr |
| Other income | ₹13 cr |
| Expenses | ₹573 cr |
| Operating profit | ₹122 cr |
| Operating margin (%) | 17.59% |
| Interest | ₹40 cr |
| Depreciation | ₹70 cr |
| Profit before tax | ₹25 cr |
| Tax | ₹9 cr |
| Net profit | ₹16 cr |
| EPS (₹) | ₹0.92 |
Operating margin of 17.59% compares with a Healthcare sector median of 22.05% across 45 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Q1 FY27 revenue growth was led by 11% year-on-year volume growth, while ARPP grew 2%.
- North Bangalore recorded 550+ new patient registrations, 300+ admissions and INR 67 million revenue in Q1 FY27.
Guidance & outlook
- HCG plans to add 1,000 beds by FY30, with 60% of the expansion coming through brownfield projects.
- North Bangalore has potential to expand its bed capacity to more than 120 beds.
- HCG expects the North Bangalore MR Linac to enhance clinical capabilities and drive patient volume.
Expansion
- North Bangalore commenced operations in May 2026 with 56 operational beds.
- HCG added 121 operational beds across North Bangalore, Ranchi, Borivali, Nashik, Hubli and Kenya.
New initiatives
- HCG commissioned an MR Linac at North Bangalore in July 2026.
- HCG operationalized a new LINAC at Rajkot, converting it into a Comprehensive Cancer Care Centre.
- HCG added new surgical robotic systems at Nashik and replaced the system at Bangalore CoE 5.
Competition
- HCG describes itself as the largest pan-India oncology-focused hospital chain.
Problems & risks
- North Bangalore start-up losses of INR 70 million and an EPCG-related provision of INR 46 million reduced reported EBITDA.
- Higher medical oncology volumes and a focus away from high-value, lower-margin therapies offset payor-mix benefits.
- East region ARPP declined 3% year on year due to case-mix changes and greater state-government scheme contribution.
What to watch
- Whether consolidated operating margin holds above 17.59%.
- Whether North Bangalore's startup losses remain near the Rs 70 million reported in Q1FY27.
- Progress in operational beds against the 121 beds added this quarter and the company's stated 1,000-bed FY30 plan.